MA32439B1 - Particules pseudovirales (vlp) de la grippe recombinées produites dans des plantes transgéniques exprimant l'hémagglutinine - Google Patents

Particules pseudovirales (vlp) de la grippe recombinées produites dans des plantes transgéniques exprimant l'hémagglutinine

Info

Publication number
MA32439B1
MA32439B1 MA33088A MA33088A MA32439B1 MA 32439 B1 MA32439 B1 MA 32439B1 MA 33088 A MA33088 A MA 33088A MA 33088 A MA33088 A MA 33088A MA 32439 B1 MA32439 B1 MA 32439B1
Authority
MA
Morocco
Prior art keywords
vlps
influenza
produced
transgenic plants
plants expressing
Prior art date
Application number
MA33088A
Other languages
Arabic (ar)
English (en)
Inventor
Aoust Marc-André D
Manon Couture
Frédéric Ors
Sonia Trépanier
Pierre-Olivier Lavoie
Michèle Dargis
LOUIS-PHILIPPE VéZINA
Nathalie Landry
Original Assignee
Medicago Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002615372A external-priority patent/CA2615372A1/fr
Application filed by Medicago Inc filed Critical Medicago Inc
Publication of MA32439B1 publication Critical patent/MA32439B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y503/00—Intramolecular oxidoreductases (5.3)
    • C12Y503/04—Intramolecular oxidoreductases (5.3) transposing S-S bonds (5.3.4)
    • C12Y503/04001—Protein disulfide-isomerase (5.3.4.1), i.e. disufide bond-forming enzyme
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F9/00—Arrangements for program control, e.g. control units
    • G06F9/06—Arrangements for program control, e.g. control units using stored programs, i.e. using an internal store of processing equipment to receive or retain programs
    • G06F9/46—Multiprogramming arrangements
    • G06F9/50—Allocation of resources, e.g. of the central processing unit [CPU]
    • G06F9/5005—Allocation of resources, e.g. of the central processing unit [CPU] to service a request
    • G06F9/5027—Allocation of resources, e.g. of the central processing unit [CPU] to service a request the resource being a machine, e.g. CPUs, Servers, Terminals
    • G06F9/505—Allocation of resources, e.g. of the central processing unit [CPU] to service a request the resource being a machine, e.g. CPUs, Servers, Terminals considering the load
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16223—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F2209/00—Indexing scheme relating to G06F9/00
    • G06F2209/50—Indexing scheme relating to G06F9/50
    • G06F2209/508—Monitor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Theoretical Computer Science (AREA)
  • Software Systems (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)

Abstract

L'invention concerne une méthode de synthèse de particules pseudovirales (VLP) de la grippe dans une plante ou une partie d'une plante. La méthode implique l'expression de HA de la grippe dans des plantes et la purification par chromatographie d'exclusion stérique. L'invention concerne également une VLP comprenant une protéine HA de la grippe et des lipides de plantes. L'invention concerne en outre un acide nucléique codant pour la protéine HA de la grippe ainsi que des vecteurs. Les VLP peuvent être utilisées pour préparer des vaccins antigrippaux ou peuvent être utilisées pour enrichir des vaccins existants.
MA33088A 2007-11-27 2010-08-13 Particules pseudovirales (vlp) de la grippe recombinées produites dans des plantes transgéniques exprimant l'hémagglutinine MA32439B1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US99060307P 2007-11-27 2007-11-27
US1327207P 2007-12-12 2007-12-12
CA002615372A CA2615372A1 (fr) 2007-07-13 2008-01-21 Particules semblables au virus grippal a comprenant de l'hemagglutinine
US2277508P 2008-01-22 2008-01-22
PCT/CA2008/001281 WO2009009876A1 (fr) 2007-07-13 2008-07-11 Pseudo-particules du virus de la grippe (vlp) comprenant de l'hémagglutinine (ha) produit dans une plante
PCT/CA2009/000032 WO2009076778A1 (fr) 2007-11-27 2009-01-12 Particules pseudovirales (vlp) de la grippe recombinées produites dans des plantes transgéniques exprimant l'hémagglutinine

Publications (1)

Publication Number Publication Date
MA32439B1 true MA32439B1 (fr) 2011-07-03

Family

ID=40795157

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33088A MA32439B1 (fr) 2007-11-27 2010-08-13 Particules pseudovirales (vlp) de la grippe recombinées produites dans des plantes transgéniques exprimant l'hémagglutinine

Country Status (18)

Country Link
US (4) US20100310604A1 (fr)
EP (2) EP2238253B1 (fr)
JP (4) JP2011509661A (fr)
KR (1) KR20100120157A (fr)
CN (2) CN101978066A (fr)
AU (1) AU2009202819B2 (fr)
CA (1) CA2707235C (fr)
CR (1) CR11612A (fr)
DK (1) DK2610345T3 (fr)
ES (1) ES2554703T3 (fr)
IL (1) IL206967A (fr)
IS (1) IS2982B (fr)
MA (1) MA32439B1 (fr)
MX (1) MX2010007962A (fr)
NZ (1) NZ587108A (fr)
PT (1) PT2610345E (fr)
WO (1) WO2009076778A1 (fr)
ZA (1) ZA201005917B (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009076778A1 (fr) 2007-11-27 2009-06-25 Medicago Inc. Particules pseudovirales (vlp) de la grippe recombinées produites dans des plantes transgéniques exprimant l'hémagglutinine
CA2615372A1 (fr) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Particules semblables au virus grippal a comprenant de l'hemagglutinine
AU2009267769B2 (en) * 2008-07-08 2015-07-16 Medicago Inc. Soluble recombinant influenza antigens
NZ590351A (en) 2008-07-18 2012-11-30 Medicago Inc HA1 domain totally or partially free of N-linked glycosylation operatively linked to a regulatory region
EP3542815A1 (fr) 2008-11-28 2019-09-25 Boehringer Ingelheim Animal Health USA Inc. Vaccin contre la grippe aviaire recombiné et ses utilisations
WO2010117786A1 (fr) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Vaccins pour le virus influenza et leurs utilisations
HUE039100T2 (hu) * 2009-06-24 2018-12-28 Medicago Inc Hemagglutinint tartalmazó kimer influenzavírus-jellegû részecskék
KR101773431B1 (ko) * 2009-09-22 2017-09-12 메디카고 인코포레이티드 식물-유래 ｖｌｐ의 제조방법
CA3028175C (fr) * 2009-12-28 2022-05-24 Sanofi Vaccine Technologies, S.A.S. Methodes de production de proteines de neuraminidase virale heterologue dans des microalgues
US10633667B2 (en) 2009-12-28 2020-04-28 Boehringer Ingelheim Animal Health USA Inc. Recombinant NDV antigen and uses thereof
EP2536425B1 (fr) 2010-02-18 2019-06-19 Icahn School of Medicine at Mount Sinai Vaccins destinés à être utilisés pour la prophylaxie et le traitement d'une maladie liée au virus de la grippe
ES2617743T3 (es) 2010-03-12 2017-06-19 Merial, Inc. Vacunas recombinantes del virus de la lengua azul y sus utilizaciones
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
JP2013542928A (ja) 2010-09-30 2013-11-28 フランバックス ソチエタ レスポンサビリタ リミテ ビロソーム粒子の生成
WO2012058762A1 (fr) 2010-11-04 2012-05-10 Medicago Inc. Système d'expression végétale
TWI526539B (zh) 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
CN103476399A (zh) * 2011-04-18 2013-12-25 独立行政法人国立精神·神经医疗研究中心 药剂递送粒子及其制造方法
WO2012145759A2 (fr) * 2011-04-21 2012-10-26 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Procédés de production de protéine et compositions associées
JP5846624B2 (ja) * 2011-05-30 2016-01-20 公益財団法人ヒューマンサイエンス振興財団 Ｈ５ｎ１型インフルエンザワクチン及び感染防御キット
KR101963792B1 (ko) * 2011-06-13 2019-07-31 메디카고 인코포레이티드 식물에서 광견병 바이러스 유사 입자 생성
EP4241785B1 (fr) 2011-09-20 2026-01-28 Icahn School of Medicine at Mount Sinai Vaccins contre le virus de la grippe et leurs utilisations
GB201116416D0 (en) * 2011-09-23 2011-11-02 Isis Innovation Composition
US11390878B2 (en) * 2011-09-30 2022-07-19 Medicago Inc. Increasing protein yield in plants
NZ622731A (en) * 2011-09-30 2016-04-29 Medicago Inc Increasing virus-like particle yield in plants
EA032089B1 (ru) * 2012-05-11 2019-04-30 Медикаго Инк. Получение ротавирус-подобных частиц в растениях
SG11201504728RA (en) 2012-12-18 2015-07-30 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US12467058B2 (en) 2013-03-28 2025-11-11 Aramis Biotechnologies Inc. Influenza virus-like particle production in plants
ES2803508T3 (es) 2013-03-28 2021-01-27 Medicago Inc Producción de partículas similares al virus de la gripe en plantas
RU2699982C2 (ru) 2014-01-10 2019-09-11 Медикаго Инк. Энхансерные элементы cpmv
US10563213B2 (en) 2014-03-27 2020-02-18 Medicago Inc. Modified CPMV enhancer elements
RU2731295C2 (ru) 2014-07-11 2020-09-01 Медикаго Инк. Модификация продуцирования белков в растениях
AU2016208999A1 (en) 2015-01-23 2017-07-13 Medicago Inc. Rotavirus-like particle production in plants
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
AU2016270979B2 (en) * 2015-06-02 2020-11-12 Sanofi Pasteur Inc. Engineered influenza antigenic polypeptides and immunogenic compositions thereof
JP2018524345A (ja) 2015-07-02 2018-08-30 メディカゴ インコーポレイテッド ジャスモン酸経路アクチベーター
CA3026096A1 (fr) 2016-06-02 2017-12-07 Sanofi Pasteur Inc. Polypeptides antigeniques de la grippe modifies et compositions immunogeniques associees
MX2018015755A (es) 2016-06-15 2019-08-29 Icahn School Med Mount Sinai Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
FR3054547B1 (fr) * 2016-07-29 2020-06-05 Angany Inc. Particules pseudo-virales et leurs utilisations
US11191825B2 (en) * 2016-09-16 2021-12-07 Vaccitech, Inc. Compositions and methods for vaccination against influenza
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
GB201708866D0 (en) * 2017-06-02 2017-07-19 Univ Cape Town Expression of chaperone proteins in planta for increased expression of heterologous polypeptides of interest
CN107058377A (zh) * 2017-06-16 2017-08-18 深圳惠升生物科技有限公司 植物作为宿主在表达中东呼吸综合征的疫苗中的应用
US11649465B2 (en) * 2017-09-11 2023-05-16 R.J. Reynolds Tobacco Company Methods and compositions for increasing expression of genes of interest in a plant by co-expression with p21
CN112400021A (zh) 2018-03-14 2021-02-23 麦迪卡格公司 植物表达增强子
CA3104297A1 (fr) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Polypeptides d'hemagglutinines du virus de la grippe en mosaique et leurs utilisations
EP3814509A4 (fr) * 2018-06-27 2022-07-27 Medicago Inc. Mutants d'hémagglutinine du virus de la grippe
WO2020035620A1 (fr) 2018-08-17 2020-02-20 Centre National De La Recherche Scientifique (Cnrs) Procédés thérapeutiques à base d'arn pour protéger des animaux vis-à-vis de bactéries pathogènes et/ou favoriser les effets bénéfiques de bactéries symbiotiques et commensales
WO2020181354A1 (fr) 2019-03-14 2020-09-17 Mitsubishi Tanabe Pharma Corporation Activateur d'expression de plante endogène
US12545718B2 (en) 2019-04-24 2026-02-10 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
EP4077684A1 (fr) * 2019-12-18 2022-10-26 Genethon Production de vecteurs viraux recombinés à partir de racines velues de plantes
EP4139331A4 (fr) * 2020-04-22 2024-10-02 Aramis Biotechnologies Inc. Suprastructure comprenant de l'hémagglutinine de la grippe modifiée à interaction réduite avec l'acide sialique
JP7627447B2 (ja) * 2020-04-22 2025-02-06 ポステック・リサーチ・アンド・ビジネス・ディヴェロップメント・ファウンデイション 三量体を形成するインフルエンザウイルス表面タンパク質由来組換え赤血球凝集素タンパク質およびその用途
CN111888390B (zh) * 2020-08-27 2021-12-14 广州白云山星群(药业)股份有限公司 夏桑菊提取物在抑制人类冠状病毒中的应用
CN120249318A (zh) * 2025-04-01 2025-07-04 华南农业大学 mRNA及其mRNA-LNP疫苗与制备方法、用途

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428147A (en) 1983-04-15 1995-06-27 Mycogen Plant Science, Inc. Octopine T-DNA promoters
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
EP0203177A4 (fr) 1984-11-29 1987-04-28 Scripps Clinic Res Polypeptides et anticorps associes a des glucoproteines virales depourvues de glucose.
JPS61265086A (ja) 1985-05-21 1986-11-22 Mitsui Toatsu Chem Inc プロトプラストの培養法
US4962028A (en) 1986-07-09 1990-10-09 Dna Plant Technology Corporation Plant promotors
US5232833A (en) 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
US6403865B1 (en) 1990-08-24 2002-06-11 Syngenta Investment Corp. Method of producing transgenic maize using direct transformation of commercially important genotypes
ATE142883T1 (de) * 1991-03-28 1996-10-15 Rooperol Na Nv Zusammensetzungen von phytosterolen mit phytosterolinen als immunmodulatoren
UA48104C2 (uk) 1991-10-04 2002-08-15 Новартіс Аг Фрагмент днк, який містить послідовність,що кодує інсектицидний протеїн, оптимізовану для кукурудзи,фрагмент днк, який забезпечує направлену бажану для серцевини стебла експресію зв'язаного з нею структурного гена в рослині, фрагмент днк, який забезпечує специфічну для пилку експресію зв`язаного з нею структурного гена в рослині, рекомбінантна молекула днк, спосіб одержання оптимізованої для кукурудзи кодуючої послідовності інсектицидного протеїну, спосіб захисту рослин кукурудзи щонайменше від однієї комахи-шкідника
US6326470B1 (en) 1997-04-15 2001-12-04 The Penn State Research Foundation Enhancement of accessibility of cellulose by expansins
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
GB9414118D0 (en) * 1994-07-13 1994-08-31 Axis Genetics Ltd Modified plant viruses as vectors of heterologous peptides
AU6504796A (en) 1995-07-20 1997-02-18 Washington State University Research Foundation Production of secreted foreign polypeptides in plant cell culture
US5773695A (en) 1996-01-26 1998-06-30 North Carolina State University Plant nuclear scaffold attachment region and method for increasing gene expression in transgenic cells
US6042832A (en) 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
US20010006950A1 (en) 1998-02-11 2001-07-05 Juha Punnonen Genetic vaccine vector engineering
US6489537B1 (en) 1998-08-07 2002-12-03 The Trustees Of The University Of Pennsylvania Phytochelatin synthases and uses therefor
IL141312A0 (en) 1998-08-11 2002-03-10 Biosource Tech Inc Method for recovering proteins from the interstitial fluid of plant tissues
US6287570B1 (en) 1998-11-23 2001-09-11 Patricia L. Foley Vaccine against swine influenza virus
FR2791358B1 (fr) 1999-03-22 2003-05-16 Meristem Therapeutics Promoteurs chimeriques d'expression, cassettes d'expression, plasmides, vecteurs, plantes et semences transgeniques les contenant et leurs methodes d'obtention
JP2003528571A (ja) 1999-04-29 2003-09-30 シンジェンタ リミテッド 除草剤抵抗性植物
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
CA2435000C (fr) 2001-01-18 2014-03-25 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Complexes de proteines oligomeres recombinantes a potentiel immunogene ameliore
KR101113432B1 (ko) * 2002-02-13 2012-02-29 위스콘신 얼럼나이 리서어치 화운데이션 인플루엔자 바이러스 벡터의 패키징을 위한 신호
US20040121465A1 (en) 2002-02-14 2004-06-24 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
CN1665934B (zh) * 2002-03-19 2010-05-26 国际植物研究所 GNTIII(UDP-N乙酰葡萄糖胺:β-D-甘露糖苷β(1,4)-N-乙酰葡萄糖胺基-转移酶III)在植物中的表达
ES2224792B1 (es) 2002-06-28 2007-02-16 Era Plantech, S.L. Produccion de peptidos y proteinas por acumulacion de cuerpos proteicos derivados de reticulos endoplasmico en plantas.
KR20060035596A (ko) * 2003-05-05 2006-04-26 보이스 톰슨 인스터튜트 포 플랜트 리서치 외래유전자도입 식물로부터 유래된 면역보호성 조성물을제조하기 위한 벡터와 세포
BRPI0410342A (pt) 2003-05-05 2006-06-20 Dow Agrosciences Llc composições imunoprofiláticas e terapêuticas estáveis derivadas de células vegetais transgênicas e processos para produção
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US7226781B1 (en) 2003-07-24 2007-06-05 Belyaev Alexander S Chaperone expression genomes
WO2006016380A2 (fr) 2004-08-13 2006-02-16 Council Of Scientific And Industrial Research Vaccin contre la rage a base de proteine g chimerique
US9155483B2 (en) 2004-12-03 2015-10-13 The Invention Science Fund I, Llc Vision modification with reflected image
ES2662118T3 (es) 2005-04-29 2018-04-05 University Of Cape Town Expresión de proteínas virales en las plantas
CN100410378C (zh) * 2005-05-09 2008-08-13 中国农业科学院生物技术研究所 编码禽流感血凝素的基因及其植物表达载体和应用
CA2615658A1 (fr) 2005-07-19 2007-01-25 Dow Global Technolgies Inc. Vaccins recombinants contre la grippe
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
AU2006279323B2 (en) 2005-08-16 2013-08-01 Merck Sharp & Dohme Corp. Influenza recombinant subunit vaccine
KR101359723B1 (ko) 2005-10-18 2014-02-05 노바백스, 인코포레이티드 기능성 인플루엔자 바이러스 유사 입자들
ES2514316T3 (es) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. Partículas similares a virus (VLPs) de Norovirus y Sapovirus
BRPI0707733B1 (pt) 2006-02-13 2019-12-31 Ibio, Inc. antígeno isolado, composição de vacina, uso da referida composição e método para produção de uma proteína de antígeno
KR20090034297A (ko) 2006-02-16 2009-04-07 더 거번먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 레프리젠티드 바이 더 세크러터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 인플루엔자에 대한 항바이러스제 및 백신
AR060565A1 (es) 2006-04-21 2008-06-25 Dow Agrosciences Llc Vacuna para la gripe aviaria y metodos de uso
WO2007130327A2 (fr) 2006-05-01 2007-11-15 Technovax, Inc. Compositions de particules de type viral (vlp) de la grippe
WO2008054540A2 (fr) 2006-05-18 2008-05-08 Pharmexa Inc. Induction de réponses immunitaires au virus de la grippe en utilisant des compositions de polypeptides et d'acides nucléiques
CA2651907C (fr) 2006-05-22 2016-12-20 Plant Bioscience Limited Systeme bipartite, procede et composition permettant l'expression constitutive et inductible de niveaux eleves de proteines etrangeres dans des plantes
US20070286873A1 (en) * 2006-05-23 2007-12-13 Williams John V Recombinant Influenza H5 Hemagluttinin Protein And Nucleic Acid Coding Therefor
US7730950B2 (en) 2007-01-19 2010-06-08 Halliburton Energy Services, Inc. Methods for treating intervals of a subterranean formation having variable permeability
WO2008148104A1 (fr) 2007-05-25 2008-12-04 Novavax, Inc. Nouvelles vlp dérivées de cellules qui n'expriment pas une matrice virale ou une protéine du noyau
DK2155880T3 (en) 2007-06-15 2016-12-05 Medicago Inc Modification of glycoproteinproduktion i plants
KR100964462B1 (ko) * 2007-07-10 2010-06-16 성균관대학교산학협력단 형질전환 식물 유래의 조류독감 바이러스 백신 및 그 제조방법
WO2009076778A1 (fr) * 2007-11-27 2009-06-25 Medicago Inc. Particules pseudovirales (vlp) de la grippe recombinées produites dans des plantes transgéniques exprimant l'hémagglutinine
CA2615372A1 (fr) 2007-07-13 2009-01-13 Marc-Andre D'aoust Particules semblables au virus grippal a comprenant de l'hemagglutinine
WO2009026397A2 (fr) 2007-08-20 2009-02-26 Fraunhofer Usa, Inc. Vaccins antigrippaux prophylactiques et thérapeutiques, antigènes, compositions et procédés
WO2009083420A1 (fr) 2007-12-28 2009-07-09 Unilever Plc Procédé de récupération d'un arôme à partir de thé
GB0800272D0 (en) 2008-01-08 2008-02-13 Plant Bioscience Ltd Protein expression systems
SG187500A1 (en) 2008-01-21 2013-02-28 Medicago Inc Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
AU2009267769B2 (en) 2008-07-08 2015-07-16 Medicago Inc. Soluble recombinant influenza antigens
NZ590351A (en) 2008-07-18 2012-11-30 Medicago Inc HA1 domain totally or partially free of N-linked glycosylation operatively linked to a regulatory region
CA2736796A1 (fr) 2008-08-27 2010-03-04 Arizona Board Of Regents For And On Behalf Of Arizona State University Systeme replicon pour production rapide et a haut rendement de vaccins et de traitements a base d'anticorps monoclonaux chez les plantes
WO2010042551A2 (fr) 2008-10-06 2010-04-15 Genvault Corporation Procédés permettant d'obtenir des lysats cellulaires à partir d'échantillons contenant des parois cellulaires
WO2010077712A1 (fr) 2008-12-09 2010-07-08 Novavax, Inc. Particule de type viral du virus syncytial respiratoire bovin (vlps)
WO2010117786A1 (fr) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Vaccins pour le virus influenza et leurs utilisations
HUE039100T2 (hu) * 2009-06-24 2018-12-28 Medicago Inc Hemagglutinint tartalmazó kimer influenzavírus-jellegû részecskék
WO2011011390A1 (fr) 2009-07-20 2011-01-27 Novavax, Inc. Protéines ha recombinantes purifiées du virus de la grippe
KR101773431B1 (ko) 2009-09-22 2017-09-12 메디카고 인코포레이티드 식물-유래 ｖｌｐ의 제조방법
JP2013520167A (ja) 2010-02-18 2013-06-06 テクノヴァックス，インコーポレイテッド 万能ウイルス様粒子（ｖｌｐ）インフルエンザワクチン
WO2012058762A1 (fr) * 2010-11-04 2012-05-10 Medicago Inc. Système d'expression végétale
KR101847908B1 (ko) 2010-11-05 2018-04-11 노바백스, 인코포레이티드 광견병 당단백질 바이러스-유사 입자(VLPs)
TWI526539B (zh) 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp
CN108611793B (zh) 2018-05-18 2020-11-20 北京化工大学 一种高强度静电纺丝聚丙烯腈基纳米碳纤维毡的制备方法

Also Published As

Publication number Publication date
JP2011509661A (ja) 2011-03-31
CA2707235A1 (fr) 2009-06-25
US11434497B2 (en) 2022-09-06
EP2238253A4 (fr) 2011-04-06
EP2610345A1 (fr) 2013-07-03
NZ587108A (en) 2013-04-26
HK1186207A1 (en) 2014-03-07
US9458470B2 (en) 2016-10-04
US20170088848A1 (en) 2017-03-30
ZA201005917B (en) 2013-10-30
MX2010007962A (es) 2010-11-10
IL206967A (en) 2014-11-30
WO2009076778A8 (fr) 2009-08-27
CN103122354A (zh) 2013-05-29
CA2707235C (fr) 2013-11-19
EP2238253B1 (fr) 2012-09-12
IL206967A0 (en) 2010-12-30
BRPI0906960A2 (pt) 2015-07-14
JP2016032477A (ja) 2016-03-10
PT2610345E (pt) 2016-01-11
CN101978066A (zh) 2011-02-16
IS2982B (is) 2017-09-15
JP2016052331A (ja) 2016-04-14
WO2009076778A1 (fr) 2009-06-25
US10190132B2 (en) 2019-01-29
DK2610345T3 (en) 2015-12-07
EP2238253A1 (fr) 2010-10-13
BRPI0906960A8 (pt) 2015-09-29
AU2009202819B2 (en) 2014-08-28
IS8919A (is) 2010-08-04
ES2554703T3 (es) 2015-12-22
JP5990207B2 (ja) 2016-09-07
CN103122354B (zh) 2018-03-23
US20130142826A1 (en) 2013-06-06
JP2014097076A (ja) 2014-05-29
US20190177739A1 (en) 2019-06-13
US20100310604A1 (en) 2010-12-09
EP2610345B1 (fr) 2015-08-19
JP6215363B2 (ja) 2017-10-18
KR20100120157A (ko) 2010-11-12
AU2009202819A1 (en) 2009-06-25
CR11612A (es) 2010-09-13

Similar Documents

Publication Publication Date Title
MA32439B1 (fr) Particules pseudovirales (vlp) de la grippe recombinées produites dans des plantes transgéniques exprimant l'hémagglutinine
EA201001198A1 (ru) Рекомбинантные вирусоподобные частицы (вч), схожие с вирусом гриппа, производящиеся в трансгенных растениях, экспрессирующих гемагглютинин
MX392585B (es) Particulas similares al virus de la influenza quimericas que comprenden hemaglutinina.
TN2009000557A1 (en) Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant
MX370690B (es) Epitopo de inmunizacion de nuevo virus de la influenza.
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
EA201201025A1 (ru) Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них
EA200970271A1 (ru) Получение вакцин против вируса гриппа без использования куриных эмбрионов
BRPI0809842A8 (pt) processo para a obtenção de linhagens de células aviárias diploides contínuas, processo de replicação de um vírus em uma linhagem de células aviárias diploides contínuas e processo de produção de peptídeos e proteínas recombinantes
MX376138B (es) Produccion de particulas similares a virus de influenza en plantas.
MX2010003202A (es) Metodo para producir virus de la gripe.
EA201170965A1 (ru) Усовершенствованные вакцины вируса человеческой папилломы и способы их использования
EP2589604A4 (fr) Protéine l1 tronquée du papillomavirus humain de type 52
DK1968632T3 (da) Forbedret influenzavaccine
IN2012DN03330A (fr)
EP2655651A4 (fr) Procédé peu coûteux d'expression et purification de protéines recombinantes dans des plantes
BR112014001950A2 (pt) métodos e composições para controlar pragas de nemátodos
NZ622731A (en) Increasing virus-like particle yield in plants
MX2020013957A (es) Mutantes de hemaglutinina del virus de la influenza.
MX385295B (es) Expresión recombinante de la proteína orf2 de pcv2b en células de insecto.
EP2137312A4 (fr) Manipulation de sénescence dans les plantes à l'aide de promoteurs modifiés
AR081155A1 (es) Plantas que tienen modificados rasgos relacionados con el rendimiento y un metodo para producirlas
AR054158A1 (es) Plantas con rendimiento aumentado y un metodo para prepararlo
EA201000769A1 (ru) Катенированные молекулы и содержащие их композиции для иммуностимуляции
EA201490758A1 (ru) Вакцины против вируса человеческой папилломы и способы их применения